Merck cervical cancer virus vaccine performs well (Reuters)


Reuters - Drugmaker Merck & Co. Inc. on Thursday
said its investigational vaccine against a sexually transmitted
virus linked to cervical cancer triggered a stronger immune
response in young adolescents than in young women in a
late-stage trial.

Read more...